# Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.

> **NCT02698410** · PHASE2 · COMPLETED · sponsor: **Ipsen** · enrollment: 40 (actual)

## Conditions studied

- Neuroendocrine Tumours

## Interventions

- **DRUG:** Lanreotide (Autogel formulation) and Temozolomide

## Key facts

- **NCT ID:** NCT02698410
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2019-02-08
- **Final completion:** 2019-06-18
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02698410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02698410, "Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02698410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*